Restriction of Radium-223 Dichloride Recommended in Europe Restriction of Radium-223 Dichloride Recommended in Europe

Use of the novel radiopharmaceutical radium-223 dichloride (Xofigo, Bayer) in prostate cancer should be restricted, according to the European Medicines Agency.News Alerts
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news